An open label, multi-centre, single arm phase IV study to evaluate the antihypertensive effect of lacidipine in mild to moderate essential hypertension patients with type 2 diabetes in Korea
Latest Information Update: 02 Jul 2023
At a glance
- Drugs Lacidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Aug 2010 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2006 New trial record.